Attached files

file filename
EX-21.1 - LIST OF SUBSIDIARIES - Jazz Pharmaceuticals plcjazzq42015ex211.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO RULES 13A-14(A) AND 15D-14(A) - Jazz Pharmaceuticals plcjazzq42015ex312.htm
EX-10.5 - MANUFACTURING SERVICES AGREEMENT - Jazz Pharmaceuticals plcjazzq42015ex105.htm
EX-10.23 - EXECUTIVE CHANGE IN CONTROL PLAN - Jazz Pharmaceuticals plcjazzq42015ex1023.htm
EX-10.22B - CASH BONUS PLAN U.S. - Jazz Pharmaceuticals plcjazzq42015ex1022b.htm
EX-10.22D - CASH BONUS PLAN OTHER - Jazz Pharmaceuticals plcjazzq42015ex1022d.htm
10-K - ANNUAL REPORT ON FORM 10-K - Jazz Pharmaceuticals plcjazz1231201510k.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO RULES 13A-14(A) AND 15D-14(A) - Jazz Pharmaceuticals plcjazzq42015ex311.htm
EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Jazz Pharmaceuticals plcjazzq42015ex231.htm
Exhibit 32.1
CERTIFICATION(1) 
Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350), Bruce C. Cozadd, Chief Executive Officer of Jazz Pharmaceuticals public limited company (the “Company”), and Matthew P. Young, Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:
 
1.
The Company’s Annual Report on Form 10-K for the year ended December 31, 2015, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and
2.
The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 23, 2016
 
/s/    Bruce C. Cozadd
Bruce C. Cozadd
Chairman and Chief Executive Officer and Director
 
/s/    Matthew P. Young
Matthew P. Young
Executive Vice President and Chief Financial Officer
 
______________________________________
(1)
This certification accompanies the Annual Report on Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Jazz Pharmaceuticals public limited company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to Jazz Pharmaceuticals public limited company and will be retained by Jazz Pharmaceuticals public limited company and furnished to the Securities and Exchange Commission or its staff upon request.